Stem cell therapy for pulmonary arterial hypertension: An update

Area of Science:

• Regenerative Medicine
• Cardiovascular Research
• Pulmonology

Background:

• Pulmonary arterial hypertension (PAH) is a fatal condition with a limited lifespan and no current cure.
• New therapeutic strategies are urgently needed to address the challenges posed by PAH.
• Stem cells are emerging as a potential treatment, but their mechanisms of action require further elucidation.

Purpose of the Study:

• To review the mechanisms by which stem cells reverse key pathological features of PAH.
• To explore how stem cells modulate signaling pathways implicated in PAH.
• To discuss the therapeutic potential and limitations of stem cell therapy for PAH.

Main Methods:

• Review of existing literature on stem cell therapy for PAH.
• Analysis of studies investigating stem cell mechanisms in PAH patients and rodent models.
• Examination of clinical trial data for mesenchymal stem cells and endothelial progenitor cells in PAH.

Main Results:

• Stem cells can reverse pulmonary vascular endothelial dysfunction, smooth muscle cell over-proliferation, and mitochondrial dysfunction in PAH.
• Stem cells modulate critical pathways including nitric oxide synthase, mitochondrial regulation, microRNAs, and STAT3-BMPR signaling.
• Genetically modified stem cells demonstrate enhanced therapeutic effects.
• Clinical trials indicate promising outcomes for mesenchymal stem cells and endothelial progenitor cells in PAH treatment.

Conclusions:

• Stem cell therapy offers a promising approach to reversing the underlying mechanisms of PAH.
• Further investigation and validation are essential to establish stem cell therapy as a definitive treatment for PAH.
• Addressing limitations and challenges will be crucial for the successful clinical translation of stem cell therapy for PAH.